L Lisata Therapeutics
L
Closed
3.16 2.6
Overview
Share price change
24h
Min
3.12
Max
3.17
Income | 1.3M -3M |
|---|---|
Sales | 100K 100K |
Profit margin | -2,954 |
Employees | 21 |
Next Earnings | 6 sie 2026 |
|---|
Market Cap | -16M 24M |
|---|---|
Previous open | 0.56 |
Previous close | 3.16 |
Lisata Therapeutics Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Lisata Therapeutics Forecast
Financials
Selling and administration expenses
Pre-tax profit
Sales
Operating profit
$
About Lisata Therapeutics
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.